Skip to contentA
aTYR PHARMA INC
A
ATYRaTYR PHARMA INC Q1 2022 · 10-Q
Revenue—
Net Income-$12.15M-$12.15MN/M vs Q1 2021 EPS Diluted-$0.44-$0.44N/M vs Q1 2021 Operating Income-$12,378,000N/M Operating Cash Flow-$10,119,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
aTYR PHARMA INC · CIK 1339970 · Engraved from SEC EDGAR
Free Cash Flowderived-$10,162,000N/M ended Mar 31, 2022 · filed May 10, 2022 · 40 d after period end